Chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule versus oxaliplatin-assisted xihuang capsules in the treatment of patients with advanced gastric cancer and its effects on T cell subsets,survival rate and adverse reactions
10.7619/jcmp.201717015
- VernacularTitle:单纯奥沙利铂-替吉奥化疗方案与化疗辅助西黄胶囊治疗晚期胃癌的疗效及对T细胞亚群、生存率及不良反应的影响
- Author:
Qiang YANG
1
;
Xiang WANG
;
Shenghui MA
;
Xin LI
Author Information
1. 河北省承德市中心医院肿瘤科
- Keywords:
gastric carcinoma;
oxaliplatin;
xihuang capsules;
T cell subsets;
survival rate
- From:
Journal of Clinical Medicine in Practice
2017;21(17):51-54
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate curative efficacy of chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule versus oxaliplatin-assisted xihuang capsules in the treatment of advanced gastric cancer and its effects on T cell subsets,survival rate and adverse reaction.Methods A total of 84 patients with gastric cancer in our hospital were randomly divided into control group and test group according to random number table method,control group was given chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule,and test group was additionally given adjuvant treatment of xihuang capsules on the basis of the control group.T cell subsets and KPS score,clinical efficacy,adverse reactions and survival rate were compared.Results The total effec tive rate in the test group was 59.5％,which was significantly higher than 38.1％ in the controlgroup (P ＜0.05).Disease control rate was 78.6％ in the test group,which was significantly higher than5 7.1 ％ in the control group (P ＜ 0.0 5).The KPS scores showed no significant difference before and after treatment in two groups (P ＞ 0.05).The levels of CD3 +,CD4 +,and CD4 + / CD8 + inthe experimental group at 4 weeks after treatment were significantly higher than that 1 week before treatment (P ＜ 0.05).Patients with adverse reactions for grade Ⅲ or Ⅳ in the test group were significantly less than that in the control group (1 case vs.5 cases,P ＜ 0.05).One and a half year survival rate and 2-year survival rate in the test group were 57.1％ and 40.5％,which were significantly higher than 35.7％,19％ in the control group (P ＜ 0.05).Conclusion Adjuvant therapy of xihuang capsules can effectively improve the immunity and survival rate,and reduce adverse reactions,so it is worthy of popularization in clinic.
